

## IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A method for lowering triglyceride levels in a subject in need thereof, comprising:  
identifying a subject having elevated postprandial triglyceride levels; and  
administering to said subject a therapeutically effective amount of an exendin or an exendin agonist, wherein said subject's postprandial triglyceride levels are lowered.
2. (Previously Presented) The method according to claim 1 wherein said exendin or exendin agonist is administered continuously.
3. (Previously Presented) The method according to claim 1 wherein said administration is by injection.
4. (Previously Presented) The method according to claim 3 wherein the injection is a subcutaneous injection.
5. (Previously Presented) The method according to claim 1 wherein about 1 µg to about 1 mg of the exendin or exendin agonist is administered per day.
6. (Previously Presented) The method according to claim 1 wherein about 1 µg to about 500 µg of the exendin or exendin agonist is administered per day.
7. (Previously Presented) The method according to claim 1 wherein about 1 µg to about 100 µg of the exendin or exendin agonist is administered per day.
8. (Previously Presented) The method according to claim 1, wherein about 3 µg to about 50 µg of the exendin or exendin agonist is administered per day.
9. (Previously Presented) The method of claim 1 wherein said subject is human.
10. (Currently Amended) A method for lowering plasma triglyceride concentrations in a subject with heart disease, comprising:  
identifying a patient with heart disease having elevated postprandial triglyceride levels; and  
administering to said subject a therapeutically effective amount of an exendin or an exendin agonist, wherein said subject's postprandial triglyceride levels are lowered.

11. (Previously Presented) The method according to any of claims 1-10 wherein said exendin is exendin-3.
12. (Previously Presented) The method according to any of claim 1-10 wherein said exendin is exendin-4.
13. (Previously Presented) The method according to any of claims 1-10 wherein said exendin agonist is selected from the group consisting of exendin-4 acid, exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4, and <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide.
14. (Previously Presented) The method according to any of claims 1-10 wherein said exendin agonist is an exendin analog or derivative.
15. (Previously Presented) The method according to any of claims 1-10, further comprising administering a therapeutically effective amount of a statin.
- 16.- 23.(Cancelled)
24. (Currently Amended) A method for lowering postprandial triglyceride levels in a subject in need thereof, comprising:
  - identifying a subject having elevated postprandial triglyceride levels; and
  - administering to said subject a therapeutically effective amount of an exendin or an exendin agonist, wherein said subject's postprandial triglyceride levels are lowered.
25. (Previously Presented) The method according to claim 24 wherein said exendin or exendin agonist is administered continuously.
26. (Previously Presented) The method according to claim 24 wherein said administration is by injection.
27. (Previously Presented) The method according to claim 26 wherein the injection is a subcutaneous injection.
28. (Previously Presented) The method according to claim 24 wherein about 1 μg to about 1 mg of the exendin or exendin agonist is administered per day.
29. (Previously Presented) The method according to claim 24 wherein about 1 μg to about 500 μg of the exendin or exendin agonist is administered per day.
30. (Previously Presented) The method according to claim 24 wherein about 1 μg to about 100 μg of the exendin or exendin agonist is administered per day.

31. (Previously Presented) The method according to claim 24, wherein about 3 µg to about 50 µg of the exendin or exendin agonist is administered per day.

32. (Previously Presented) The method of claim 24 wherein said subject is human.

33. (Previously Presented) The method according to any of claims 24-32 wherein said exendin is exendin-3.

34. (Previously Presented) The method according to any of claim 24-32 wherein said exendin is exendin-4.

35. (Previously Presented) The method according to any of claims 24-32 wherein said exendin agonist is selected from the group consisting of exendin-4 acid, exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4, and <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide.

36. (Previously Presented) The method according to any of claims 24-32 wherein said exendin agonist is an exendin analog or derivative.

37. (Previously Presented) The method according to any of claims 24-32, further comprising administering a therapeutically effective amount of a statin.

38.-40. (Cancelled)

41. (Previously Presented) The method according to claim 1 wherein said exendin or exendin agonist is selected from the group consisting of exendin-3, exendin-4, exendin-4 acid, exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4, and <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide.